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Objective: This study was undertaken to assess the impact of immunosuppressive and immunomodulatory therapies
on the severity of coronavirus disease 2019 (COVID-19) in people with multiple sclerosis (PwMS).
Methods: We retrospectively collected data of PwMS with suspected or confirmed COVID-19. All the patients had
complete follow-up to death or recovery. Severe COVID-19 was defined by a 3-level variable: mild disease not requir-
ing hospitalization versus pneumonia or hospitalization versus intensive care unit (ICU) admission or death. We evalu-
ated baseline characteristics and MS therapies associated with severe COVID-19 by multivariate and propensity score
(PS)-weighted ordinal logistic models. Sensitivity analyses were run to confirm the results.
Results: Of 844 PwMS with suspected (n = 565) or confirmed (n = 279) COVID-19, 13 (1.54%) died; 11 of them were in
a progressive MS phase, and 8 were without any therapy. Thirty-eight (4.5%) were admitted to an ICU; 99 (11.7%) had
radiologically documented pneumonia; 96 (11.4%) were hospitalized.
After adjusting for region, age, sex, progressive MS course, Expanded Disability Status Scale, disease duration, body
mass index, comorbidities, and recent methylprednisolone use, therapy with an anti-CD20 agent (ocrelizumab or
rituximab) was significantly associated (odds ratio [OR] = 2.37, 95% confidence interval [CI] = 1.18–4.74, p = 0.015) with
increased risk of severe COVID-19. Recent use (<1 month) of methylprednisolone was also associated with a worse out-
come (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001). Results were confirmed by the PS-weighted analysis and by all the
sensitivity analyses.
Interpretation: This study showed an acceptable level of safety of therapies with a broad array of mechanisms of
action. However, some specific elements of risk emerged. These will need to be considered while the COVID-19 pan-
demic persists.
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The COVID-19 pandemic and the many questionsabout the postpandemic period complicate the man-
agement of patients who need therapies that impact on
the immune system. Data available so far are overall
reassuring, excluding major safety issues.1–4 However, the
robustness of results is not optimal due to the relatively
small samples, collected in a situation of urgency. Further-
more, for most of the autoimmune diseases, many possible
therapies are available, thus increasing the heterogeneity of
the datasets. It is therefore necessary to rely on larger and
better characterized case series to improve data quality and
relevance. The results will inform clinical decisions that
will have a long-term impact, given the chronicity of the
diseases, the duration of therapies, and the long-lasting
effects of some treatments.
Multiple sclerosis (MS) is the major cause of neuro-
logical disability in young adults, with approximately 2.3
million people affected worldwide.5 Up to 70% of people
with MS (PwMS) are treated with disease-modifying ther-
apies (DMTs) that impact on the immune response and
may carry an increased probability of infection.6 This risk
must be balanced against the consequences of poorly con-
trolled MS. Hence, reliably assessing the risk of coronavi-
rus disease 2019 (COVID-19) in these patients is an
important public health issue, and more data are needed
to guide clinical practice, as pointed out in recent
reviews.7 So far, the largest study based on data is the
paper on the French cohort,3 but the sample size did not
allow drawing conclusions about the association of DMTs
and COVID-19 severity.
We present the results of an observational study on
PwMS with a confirmed or suspected COVID-19 infec-
tion, based on clinician-reported data. The study was con-
ducted in Italy, a high-prevalence area for MS8 that was
the first European country to suffer the effects of the pan-
demic. The results are presented after the preplanned sam-
ple size needed to reach conclusions on the effect of
DMTs on COVID-19 severity was reached.
Patients and Methods
Data Sources
We obtained clinician-reported demographic and clinical
data on PwMS with a confirmed or suspected COVID-19
infection from 85 Italian MS centers (Supplementary
Table S2). We used a common web-based electronic case
report form (eCRF) to collect the data and a unified pro-
tocol to analyze them. Data were obtained after data-
sharing agreements between the Italian MS Society, the
Italian Neurological Society, the University of Genoa, and
all the MS centers involved. Demographic, MS history,
COVID-19 infection, and follow-up data were collected.
The study was approved by the regional ethics committee
of Liguria (University of Genoa; n 130/2020–DB id
10433) and at a national level by the Italian Medicines
Agency.
Study Population
We included adult MS patients who had been in contact
with their neurologist because of a confirmed or suspected
infection by severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) during the observation period (January
15 to September 10, 2020). The confirmed cases were
those with a positive test (reverse transcriptase polymerase
chain reaction on nasal and pharyngeal swabs) for SARS-
CoV-2 or a positive serological test obtained at any point
during the observation period; the suspected cases were
those who had radiological findings or symptoms highly
suggestive of SARS-CoV-2 infection, according to medical
judgment (cough, fever, shortness of breath, sudden onset
of anosmia, ageusia, dysgeusia), and/or had close contact
with a confirmed COVID-19 case in the 14 days prior to
the onset of symptoms. Data were collected retrospectively
from the first contact until an outcome (death or recov-
ery), taking as baseline the day of symptoms appearance.
The first contact was a hospital visit, a phone call, or a
web-based visit, upon patients’ or clinicians’ request. Cli-
nicians collected data by reviewing patients’ clinical charts.
Variables Assessed
Collected data are detailed in the eCRF. We collected
demographic data, including age, sex, body mass index
(BMI), patient-reported race and ethnic group, work sta-
tus, number of cohabitants and number of cohabitants
positive for SARS-CoV-2 infection, patient-reported
smoking and drinking status, and comorbidities; MS his-
tory data, including type of MS (relapsing–remitting MS
[RRMS], primary progressive, or secondary progressive),
disease onset date, Expanded Disability Status Scale
(EDSS), DMTs at the date of symptoms start, and date of
last treatment dose; and COVID-19 infection data,
including suspected geographic area of infection, symp-
toms, laboratory and radiological data, hospitalization,
pneumonia and severity of pneumonia according to radio-
logical examinations and ventilation support, therapies for
COVID-19, intensive care unit (ICU) admission, and
recovery or death.
Each week a query for follow up update was sent to
all centers, until they filled the outcome report (death or
recovery).
End Points
We run 2 main analyses on the following primary end-
points: (1) observed number of deaths over the whole
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follow-up; and (2) severe COVID-19 characterized by a
3-level variable; the highest severity level was death or
ICU admission, the intermediate severity level was diagno-
sis of pneumonia or hospitalization, and the lowest sever-
ity level was a milder disease with no need for
hospitalization or documented diagnosis of pneumonia.
Statistical Analysis
The web-based data collection started on March 1, 2020
and closed for the analysis on September 10, 2020. The
first date of symptom appearance retrospectively reported
was January 15, 2020. All the patients had complete
follow-up to death or recovery.
For the sample size calculations, we determined that
800 patients were needed, assuming a rate of severe out-
comes (death, ICU admission, pneumonia, or hospitaliza-
tion) of 20% in the reference group and a comparison
group made of 15% of the full cohort, to have a power of
90% to detect an increased risk of severe outcome in the
comparison group quantified by an odds ratio (OR) = 2.0
at a confidence level of 0.05.
To make efficient use of the available data, we used
multiple imputation of missing values for missing baseline
data. Imputation was performed using chained equations,9
where each incomplete variable is imputed by a separate
model and implemented trough the "mice" R package.
Continuous variables (age, height, weight, BMI, and dis-
ease duration) were parameterized as numeric data and
imputed with the predictive mean matching method,
whereas polytomous logistic regression was used for the
unordered categorical variables (such as MS phenotype).
EDSS and disease duration were used to impute the MS
phenotype; age and MS phenotype were used to impute
disease duration; age, height, or weight was used to
impute BMI.
To assess risk factors at symptoms onset for a severe
disease course, we ran a multivariate ordinal logistic regres-
sion assuming proportional ORs with severe outcome
(defined as a 3-level factor) as the dependent variable, after
assessing that the assumptions of proportional odds were
satisfied. The ORs reflect the multiplicative change in the
odds of being at a higher level of the dependent variable
for every one-unit increase of the independent variable.
The multivariate model included age, sex, BMI, EDSS,
disease duration, MS disease phase (RRMS vs progressive),
presence of comorbidities, methylprednisolone use within
1 month since COVID-19 symptoms onset, and DMT
class as independent variables, stratified by macroregion
(defined as Lombardy; Northern Italy, including Pied-
mont, Veneto, Emilia-Romagna, and Liguria; and the rest
of Italy). DMT class was coded as an 8-level variable as no
therapy, interferon, glatiramer-acetate, teriflunomide,
dimethyl fumarate, natalizumab, anti-CD20 (rituximab or
ocrelizumab), or other. Alemtuzumab and cladribine were
grouped in the “other” group, because the number of
patients in these two therapeutic arms was too low to
draw meaningful conclusions. “No therapy” was used as
the reference category. We also ran the same ordinal logis-
tic analysis after a multinomial propensity score
(PS) weighting, as an alternative method to balance the
differences of baseline characteristics among patients
treated with different DMTs. The weights were calculated
using an iterative robust approach based on the General-
ized Boosted Model (GBM).10 The balance among treat-
ment groups was defined by the standardized mean
difference, and the optimal GBM iteration was found by
minimizing this quantity.
Results were also presented taking dimethyl fuma-
rate, which is the most frequently used therapy in Italy, as
the reference therapy group (Supplementary Appendix).
Additional analyses were focused on the anti-CD20 thera-
pies using the same multivariate ordinal logistic model
adjusted for all the baseline variables; we investigated the
effect of being on anti-CD20 versus not being on anti-
CD20, the effect of the distance from last infusion (0–-
3 months, >3 months), and the effect of the time since
therapy start (<6 months, 6–12 months, >12 months).
Sensitivity analyses were run by repeating all the ana-
lyses on the subgroup of confirmed cases only, in the sub-
group of patients with a RRMS course, in a model
including only patients with complete baseline data with
no imputation and using a leave one out procedure rerun-
ning the analysis excluding one of the 3 major centers
(Brescia, Bergamo, Milan) at a time (Supplementary
Appendix).
Role of the Funding Source
Roche donated the web-based platform for data collection.
Roche did not have any role in study design; in analysis
and interpretation of data; in the writing of the report; or
in the decision to submit the paper for publication.
Results
Patients Characteristics
On September 10, 844 PwMS with complete follow-up
from first contact to the outcome (recovery or death) from
85 centers were included in the dataset (Supplementary
Appendix). Thirty-four percent (286/844) of patients were
from 3 centers in Lombardy (ASST Spedali Civili, Bre-
scia-Montichiari; Papa Giovanni XXIII Hospital,
Bergamo; and San Raffaele Hospital, Milan); the distribu-
tion of patients by region is shown in Supplementary
Table S3.
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TABLE 1. Baseline Demographic and Clinical Characteristics of Included Patients
Characteristic Overall, N = 844 Suspected, n = 565 Confirmed, n = 279
Age, n (%)
<40 yr 279 (33.1) 203 (35.9) 76 (27.2)
40–59 yr 471 (55.8) 312 (55.2) 159 (57.0)
60–79 yr 92 (10.9) 50 (8.8) 42 (15.1)
≥80 yr 2 (0.2) 0 (0.0) 2 (0.7)
Female sex, n (%) 593 (70.3) 410 (72.6) 183 (65.6)
BMI, mean (SD) 23.82 (4.37) 23.61 (4.37) 24.28 (4.37)
Comorbidities, n (%) 188 (22.3) 115 (20.4) 73 (26.2)
MS phenotype, n (%)
Primary progressive 44 (5.2) 24 (4.2) 20 (7.2)
Relapsing–remitting 676 (80.1) 469 (83.0) 207 (74.2)
Secondary progressive 91 (10.8) 46 (8.1) 45 (16.1)
Missing data 33 (3.9) 26 (4.6) 7 (2.5)
MS disease duration,
median (IQR)
10.2 (4.7–17.1) 9.6 (4.3–16.2) 11.8 (5.4–18.5)
EDSS, median (IQR) 2 (1.50–4) 2 (1.50–3.50) 2 (1.50–4)
MS treatment, n (%)
Dimethyl fumarate 174 (20.6) 131 (23.2) 43 (15.4)
Fingolimod 94 (11.1) 59 (10.4) 35 (12.5)
Ocrelizumab 89 (10.5) 58 (10.3) 31 (11.1)
Natalizumab 85 (10.1) 51 (9.0) 34 (12.2)
Interferon 73 (8.6) 52 (9.2) 21 (7.5)
Copaxone 70 (8.3) 52 (9.2) 18 (6.5)
Teriflunomide 64 (7.6) 37 (6.5) 27 (9.7)
Alemtuzumab 14 (1.7) 11 (1.9) 3 (1.1)
Cladribine 11 (1.3) 7 (1.2) 4 (1.4)
Azathioprine 10 (1.2) 4 (0.7) 6 (2.2)
Rituximab 5 (0.6) 4 (0.7) 1 (0.4)
Methotrexate 1 (0.1) 1 (0.2) 0 (0.0)
Mitoxantrone 1 (0.1) 1 (0.2) 0 (0.0)
Other 2 (0.2) 2 (0.4) 0 (0.0)
None 151 (17.9) 95 (16.8) 56 (20.1)
Previous methylprednisolone,
n (%)
26 (3.1) 16 (2.8) 10 (3.6)
BMI = body mass index; EDSS = Expanded Disability Status Scale; IQR = interquartile range; MS = multiple sclerosis; SD = standard deviation.
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Table 1 reports the baseline demographic and clinical
characteristics of the cohort. The mean age was 45 years
(range = 18–82), the percentage of females was 70.3%,
the median EDSS was 2 (interquartile range [IQR]
= 1.50–4), and the proportion of progressive patients was
16%. Six hundred ninety-three (82%) patients were
treated with a DMT at the time of COVID-19 presumed
symptoms onset.
Three hundred eighty-four patients (45.5%) had at
least one laboratory test executed for the COVID-19 diag-
nosis; 307 (36.4%) patients were tested in the active phase
with a swab and 127 (15.0%) had a serological test after
recovery. Overall, 279 (33.1%) were classified as con-
firmed cases. Because the test during the pandemic peak
was done only in the most severe patients, confirmed cases
are expected to be more severe than suspected cases. In
the confirmed cases subgroup, there was a higher propor-
tion of older subjects than in the suspected cases subgroup
(>60 years = 16% vs 9%) and more patients in the pro-
gressive MS phase (23% vs 12%).
The baseline characteristics of the cohort according
to DMT received are reported in Table 2; patients with
no therapy were older (mean age = 53.4 years), with a
higher EDSS (mean EDSS = 5.5) and with a higher pro-
portion of progressive patients (45.7%) than patients
treated with DMTs. Among treated patients, those treated
with interferon, glatiramer-acetate, or teriflunomide were
older than those in other DMT groups, and patients
treated with anti-CD20 had a higher EDSS (mean
EDSS = 3) and a larger portion of progressive patients
(25.6%) than those treated with other DMTs, but not
larger than the untreated group.
Thirteen (1.54%) patients died, and their character-
istics are described in Table 3; 8 of them were PwMS with
no therapy, all in a progressive disease phase (1 primary
progressive MS, 7 secondary progressive MS). Five of
them were treated (rituximab, ocrelizumab, natalizumab,
glatiramer-acetate, dimethyl fumarate), and only 2 of them
were in a RRMS phase (glatiramer-acetate and
natalizumab). The mean time from symptoms to death
was 18 days (range = 5–54 days).
Risk Factors for a Severe COVID-19 Outcome
Thirty-eight (4.5%) patients were admitted to an ICU
(7 of them died); 99 cases (11.7%) of radiologically docu-
mented pneumonia were reported; 96 patients (11.4%)
were hospitalized. Forty-four patients (5.2%) were in the
highest severity class (death or ICU admission), and
92 patients (10.9%) were in the intermediate severity class
(pneumonia or hospitalization). Twenty-six patients
(3.1%) received methylprednisolone in the month preced-
ing the first symptoms of COVID-19.
Risk factors for severe COVID-19 in univariate, mul-
tivariate, and PS-weighted analysis are reported in Table 4.
The assumptions of proportional odds were satisfied. Older
age, male sex, higher EDSS, longer MS duration, presence
of comorbidities, and progressive MS course were all risk
factors for a more severe disease in univariate analysis.
Methylprednisolone use within 1 month before COVID-
19 symptoms onset was associated with increased risk
(OR = 3.38, 95% confidence interval [CI] = 1.49–7.67,
p = 0.004). Taking no therapy as the reference category
indicated a reduced risk for all the DMTs, with OR rang-
ing from 0.34 to 0.50, except for the anti-CD20 therapies
(ocrelizumab/rituximab, OR = 0.94). When adjusting the
OR in the multivariate model, the risk factors with a signif-
icant impact on COVID-19 severity were age, sex, EDSS,
recent use of methylprednisolone, and anti-CD20 therapy.
Age and EDSS fully explained the apparent risk associated
with no therapy as compared to the other DMTs, and the
only treatment associated with a higher risk of a severe
COVID-19 disease was anti-CD20 therapy (OR = 2.37,
95% CI = 1.18–4.74, p = 0.015). Also, the increased risk
associated with the use of recent methylprednisolone was
confirmed (OR = 5.24, 95% CI = 2.20–12.53, p = 0.001).
The PS-weighted characteristics of patients according to the
different DMTs received are reported in Supplementary
Table S11. The DMT effects on COVID-19 severity are
replicated by the PS-weighted analysis. The OR for anti-
CD20 therapy was 3.91 (95% CI = 1.71–8.91, p = 0.001).
The results taking dimethyl fumarate as the reference
category are reported in the Supplementary Appendix and
are in line with the above results. All the sensitivity ana-
lyses confirmed these findings; the anti-CD20–treated
patients had an OR = 2.62 (p = 0.05) in the subgroup of
confirmed cases, an OR = 2.87 (p = 0.03) in the subgroup
of RRMS patients, and an OR = 2.69 (p = 0.026) using
only complete baseline data with no imputation
(Supplementary Appendix).
A further result that deserves attention is the risk
reduction observed in patients treated with interferon
(OR = 0.67); however, this does not reach a statistical sig-
nificance. Among the 73 patients on interferon, no ICU
admissions or deaths were recorded.
To give an idea of the absolute risk of severe
COVID-19 according to DMT, Figure reports the per-
centage of patients with severe events (pneumonia, hospi-
talization, ICU, or death) in the group treated with anti-
CD20, in the untreated group, and in the group treated
with other DMTs. To adjust these values for the con-
founding factors, the figure was restricted to patients
<65 years old and with EDSS < 6.5 (n = 733), and pres-
ented separately for the RRMS (n = 675) and progressive
MS (n = 58) groups. The percentage of subjects with
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Age, mean (SD) 53.4 (13.4) 47.5 (10.5) 45.7 (11.3) 49.1 (9.4) 41.4 (10.9) 44.2 (9.5) 37.9 (9.8) 42.0 (10.0) 42.2 (13.8)
Female sex, n (%) 104 (68.9) 53 (72.6) 48 (68.6) 44 (68.8) 114 (65.5) 74 (78.7) 64 (75.3) 64 (68.1) 28 (71.8)
BMI, mean (SD) 24.6 (4.6) 24.3 (2.7) 25.2 (5.0) 24.7 (4.5) 23.3 (4.1) 23.9 (5.2) 22.7 (4.1) 22.6 (3.7) 23.2 (3.8)
MS phenotype,
n (%)
Primary progressive 22 (14.6) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0) 2 (2.1) 1 (1.2) 16 (17.0) 2 (5.1)
Relapsing–remitting 65 (43.0) 65 (89.0) 64 (91.4) 59 (92.2) 165 (94.8) 81 (86.2) 83 (97.6) 67 (71.3) 27 (69.2)
Secondary progressive 47 (31.1) 6 (8.2) 2 (2.9) 3 (4.7) 5 (2.9) 9 (9.6) 0 (0.0) 9 (9.6) 10 (25.6)
Missing data 17 (11.3) 2 (2.7) 3 (4.3) 2 (3.1) 4 (2.3) 2 (2.1) 1 (1.2) 2 (2.1) 0 (0.0)
MS disease duration,
median yr (IQR)
16.2 (8–23) 12.0 (6–19) 10.1 (5–17) 11.4 (6–15) 5.5 (3–13) 11.8 (7–18) 9.1 (5–15) 8.2 (4–13) 12.9 (5–18)
EDSS, median (IQR) 5.5 (2–7) 1.5 (1–2.5) 1.5 (1–2) 2.0 (1.5–3) 1.5 (1–2) 2.0 (1.5–3) 2.0 (1.5–3) 3.0 (1.5–4.5) 3.0 (1.5–6)
Methylprednisolone,b n
(%)
9 (6.0) 2 (2.7) 1 (1.4) 2 (3.1) 4 (2.3) 4 (4.3) 1 (1.2) 1 (1.1) 2 (5.1)
aOcrelizumab or rituximab.
bOne month before symptoms onset.
BMI = body mass index; DMF = dimethyl fumarate; EDSS = Expanded Disability Status Scale; FTY = fingolimod; GA = glatiramer-acetate; IFN =
interferon; IQR = interquartile range; MS = multiple sclerosis; Nat = natalizumab; SD = standard deviation; Teri = teriflunomide.





Phase EDSS Therapy Comorbidities
M, 63 33 SPMS 7 No therapy Diabetes
M, 67 2 PPMS 7.5 No therapy CHD, hypertension, HBV
M, 68 21 SPMS 6 Dimethyl
fumarate
Cerebrovascular disease, hypertension, depression,
TBC
F, 57 20 SPMS 9 No therapy No
M, 76 17 SPMS 6.5 No therapy CHD, hypertension, depression, dyslipidemia
F, 52 1 RRMS 5 Natalizumab No
F, 50 27 SPMS 6 Ocrelizumab No
M, 59 33 SPMS 9 No therapy No
F, 68 19 SPMS 5.5 No therapy No
F, 54 20 SPMS 7 Rituximab No
M, 64 10 RRMS 2 Glatiramer-
acetate
No
M, 63 33 SPMS 6.5 No therapy Diabetes, bipolar disorder
M, 60 30 SPMS 9 No therapy Hypertension, cerebrovascular disease, CHD
CHD = coronary heart disease; F = female; HBV = hepatitis B virus; M = male; PPMS = primary progressive multiple sclerosis; RRMS = relapsing–
remitting multiple sclerosis; SPMS = secondary progressive multiple sclerosis; TBC = tuberculosis.
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severe events was higher in the group of patients treated
with anti-CD20 both in the RRMS and in the progressive
MS patients; in the RRMS group, the proportion of
patients deceased or admitted to ICU in the anti-CD20
group was 6.1%, versus 4.2% in the untreated and 2.2%
in the other DMTs group. In the progressive MS group,
it was 12.5% in the anti-CD20 group, 10.5% in the
untreated group, and 4.3% in the other DMTs group.
The percentage of patients with an intermediate severity
(pneumonia or hospitalization) had the same trend of
increase in the anti-CD20 group.
The increase of risk associated with anti-CD20 was
maintained on hard end points (death or ICU admission),
even if the small number of events did not allow this to
reach statistical significance (Supplementary Appendix).
The adjusted OR for anti-CD20 therapy versus all
the other therapies was 2.37 (95% CI = 1.36–4.12,
p = 0.002). Exploratory analyses revealed no association
between COVID-19 severity and the time passed since the
last anti-CD20 infusion (OR = 2.77, 95% CI = 1.31–
5.89, p = 0.012 for last infusion within 3 months and
OR = 2.05, 95% CI = 0.97–4.28, p = 0.023 for last infu-
sion before 3 months), whereas there was a trend with ther-
apy duration; as compared to PwMS treated with other
therapies, patients on anti-CD20 therapy for <6 months
had an OR = 1.65 (95% CI = 0.56–4.90, p = 0.36),
TABLE 4. Univariate, Multivariate, and PS-Weighted Ordinal Logistic Regression Models Evaluating Risk Factors
for Severe Coronavirus Disease 2019a
Univariate Analysis, n = 844b Multivariate Analysis, n = 844b PS Analysis, n = 844b
Variable OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age, yr 1.06 (1.04–1.08) <0.001 1.06 (1.03–1.08) <0.001 1.06 (1.03–1.10) 0.001
Sex, F vs M 0.64 (0.40–1.03) 0.068 0.69 (0.45–1.04) 0.076 0.83 (0.50–1.39) 0.49
Progressive vs RRMS 4.14 (2.70–6.35) <0.001 1.59 (0.81–3.01) 0.18 1.76 (0.70–4.40) 0.23
EDSS 1.33 (1.22–1.45) <0.001 1.07 (0.93–1.22) 0.40 1.08 (0.86–1.35) 0.50
Disease duration, yr 1.04 (1.02–1.06) <0.011 1.00 (0.98–1.03) 0.99 0.99 (0.96–1.02) 0.57
BMI 1.01 (0.97–1.05) 0.53 0.98 (0.94–1.02) 0.44 0.99 (0.93–1.02) 0.74
Comorbidities, yes 1.70 (1.13–2.56) 0.012 0.93 (0.58–1.47) 0.74 0.82 (0.48–1.42) 0.48
Methylprednisolonec 3.38 (1.49–7.67) 0.004 5.24 (2.20–12.53) 0.001 2.51 (0.99–6.44) 0.05
DMT
No therapyd 1 (ref) 1 (ref) 1 (ref)
Interferon 0.35 (0.15–0.79) 0.012 0.67 (0.28–1.65) 0.39 0.71 (0.29–1.78) 0.48
Glatiramer-acetate 0.34 (0.14–0.81) 0.015 0.77 (0.29–2.00) 0.59 1.19 (0.30–4.87) 0.80
Teriflunomide 0.48 (0.21–1.07) 0.07 0.86 (0.36–2.08) 0.74 1.17 (0.41–3.63) 0.76
Dimethyl fumarate 0.38 (0.20–0.70) 0.002 1.12 (0.55–2.30) 0.75 1.29 (0.58–2.87) 0.62
Natalizumab 0.35 (0.16–0.76) 0.009 1.30 (0.53–3.22) 0.57 1.77 (0.61–5.07) 0.29
Fingolimod 0.50 (0.26–0.98) 0.04 1.19 (0.57–2.52) 0.64 1.48 (0.66–3.34) 0.34
Anti-CD20e 0.94 (0.52–1.08) 0.85 2.37 (1.18–4.74) 0.015 3.91 (1.71–8.91) 0.001
Other 0.38 (0.14–1.04) 0.06 0.71 (0.28–2.65) 0.39 1.50 (0.40–5.71) 0.55
aIntensive care unit or death vs hospitalization or pneumonia vs milder symptoms not requiring hospitalization and no documented pneumonia.
bAll the analyses are adjusted for macroregion (Lombardy; Northern Italy, including Veneto, Emilia-Romagna, Piedmont, and Liguria; and the rest of
Italy).
cOne month before symptoms onset.
dNo therapy was chosen as the reference class.
eOcrelizumab or rituximab.
BMI = body mass index; CI = confidence interval; DMT = disease-modifying therapy; EDSS = Expanded Disability Status Scale; F = female; M =
male; OR = odds ratio; PS = propensity score; RRMS = relapsing–remitting multiple sclerosis.
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patients on anti-CD20 therapy for 6–12 months had an
OR = 2.24 (95% CI = 0.91–5.55, p = 0.08), and patients
on anti-CD20 therapy for >12 months had an OR = 2.98
(95% CI = 1.37–6.46, p = 0.006; Supplementary
Appendix).
No severe outcomes (no pneumonia, hospitalization,
ICU, or death) were observed in the 11 patients treated with
cladribine or in the 14 patients treated with alemtuzumab.
Discussion
This study shows an acceptable level of safety of immuno-
modulatory and immunosuppressive therapies in MS dur-
ing the COVID-19 pandemic. However, two results
deserve attention.
First, 11 of 13 deaths occurred in persons with
advanced disease and disability (median EDSS = 7). The
median age of people who died was 63 years versus a
median age of 45 years for those who recovered. Higher
EDSS was associated in multivariate analysis with
COVID-19 severity also in the French MS population.3
These findings strengthen the need to enforce prevention
strategies for people with advanced disability and older age
during the pandemic.11
Second, we observed an increased frequency of a
severe COVID-19 in people treated with anti-CD20 ther-
apies compared to other DMTs. Smaller case series
suggested an increased susceptibility to COVID-19 in
PwMS taking B-cell–depleting monoclonal
antibodies,12–14 without major effects on the severity of
COVID-19.13–15 In the largest study published so far (the
French study), DMT exposure was not included in the
multivariate model. The results of the univariate analysis
are very similar to those presented here.3 It will be infor-
mative to evaluate the OR for the impact of DMTs on
severity in the French cohort in the multivariate model, to
check the size of effect, irrespective of the statistical signifi-
cance. Data are available about the general risk of infec-
tions during DMTs for MS; a nationwide Swedish cohort
examined the infection risks in PwMS treated with
DMTs.16 In that study, rituximab was associated with the
highest rate of serious infections. However, the use of her-
pes antivirals was lower with rituximab compared to
fingolimod and natalizumab; ocrelizumab clinical trials
reported an increased risk of respiratory tract
infections,17,18 and safety issues emerged in diseases other
than MS.19 With respect to the association with treatment
duration, it has been shown that long-term anti-CD20
treatment is associated with the risk of hyp-
ogammaglobulinemia in neuromyelitis optica-spectrum
disorder.20 A protracted treatment may impact on the pro-
tective, anti–SARS-CoV-2 humoral response21 and on a
pre-existing humoral and cellular immune repertoire,
recently described in unexposed individuals.22,23
We did not observe a link between time to last infu-
sion of ocrelizumab and COVID-19 risk. This prelimi-
nary result needs to be confirmed, but it is consistent with
the idea that the immunological effects of ocrelizumab
may last longer than 6 months. Reducing the frequency of
dosing, or adjusting it according to the monitoring of B-
cell repopulation kinetics in individual patients,20 may
maintain efficacy while limiting the risk of infection.24 A
similar strategy deserves attention also in view of future
vaccinations.25 However, it may not be without risks
linked to the re-expansion of autoreactive B cells.26
The role of interferon treatment and the severity of
COVID-19 is of high interest. Our data indicated a
decrease of risk associated with interferon, even if it did
not reach statistical significance. The majority of labora-
tory studies are in line with this preliminary observation,
suggesting that supplementing type I interferons may cir-
cumvent a defective response that, in people with severe
COVID-19, may depend on various mechanisms includ-
ing the presence of anti-interferon autoantibodies,27 a
FIGURE: Percentage of patients with pneumonia/
hospitalization and intensive care unit (ICU)/death in the
subgroup of subjects with age < 65 years and Expanded
Disability Status Scale < 6.5, according to multiple sclerosis
(MS) phenotype (relapsing–remitting vs progressive MS), in
the anti-CD20, no therapy, and other therapies groups. DMT
= disease-modifying therapy.
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genetically defective type I interferon response,28,29 or the
ability of SARS-CoV-2 to neutralize the antiviral effects of
type I interferons.30 A recent clinical trial of interferon
beta-1b and lopinavir–ritonavir in Middle East respiratory
syndrome31 supports this hypothesis, but a negative trial
of interferon beta-1b, alone or in combination with
lopinavir, does not.32 It is possible that timing in the
administration of type I interferons is crucial, as early ther-
apy is associated with favorable clinical responses.33 This
is in accord with our observation in patients who are
already under interferon beta therapy when they develop
COVID-19.
Importantly, methylprednisolone in the month pre-
ceding the first symptoms of COVID-19 was significantly
associated with a worse outcome. This aspect was not con-
sidered in previous reports, is in agreement with data in
other autoimmune diseases,34 and is relevant in assessing
the risk of DMTs (ie, COVID-19 risk vs steroid-sparing
potential).
This study has limitations that must be considered
when evaluating the results. First, we included in the
study not only confirmed but also suspected cases. For
this reason, we cannot exclude that the suspected cases
suffered from infections other than COVID-19. We took
the decision of including suspected cases because, during
the pandemic peak in Italy, only the most severe cases
(often after hospitalization) were tested. Hence, including
only confirmed cases would have limited the representa-
tiveness of our sample. The inclusion of patients suffering
from non–COVID-19 infections might have diluted the
effect of the detected association, resulting in a conserva-
tive approach. Furthermore, we reran all the main analyses
on the subgroup of confirmed cases, obtaining similar and
even stronger results, despite the smaller sample size. A
second relevant bias might derive from differences in
awareness and expectations of risks in patients receiving
therapies with stronger immunosuppressive effect. This
might have favored more frequent contacts with treating
neurologists, resulting in increased attention to
ocrelizumab or rituximab patients. However, the same
should have been true also for other intravenous therapies.
Finally, although the multivariate analysis adjusts the
effect of DMTs on COVID-19 severity for the main con-
founding factors, we cannot exclude that some residual
confounding can partly explain the observed associations.
Overall, this study shows an acceptable safety profile
of DMTs in MS during the COVID-19 pandemic. The
differences that emerged among the various DMTs are in
agreement with previous knowledge about infections in
PwMS. The results are also plausible based on current bio-
logical knowledge, although the exact mechanisms that
affect the risk of COVID-19 remain uncertain. It will be
important to look at other ongoing studies35 to verify
whether they confirm our findings and to compare the
new clinical insight in other autoimmune diseases. This
may stimulate new laboratory research and shed new light
on the biology of SARS-CoV-2 infection and on the path-
ophysiology of the different autoimmune diseases.
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